Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer

Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer

“…Local treatment of metastases mainly included palliative radiotherapy to alleviate pain and prevent paralysis due to bone metastases and was rarely used for systemic cancer control. However, recently, next-generation imaging tests including choline positron emission tomography (PET) [ 1 , 2 , 3 ], whole-body magnetic resonance diffusion-weighted imaging with background suppression (DWIBS) [ 3 , 4 , 5 ], fluorocholine PET [ 5 , 6 , 7 ], and prostate-specific membrane antigen (PSMA)-PET [ 8 , 9 , 10 ], have made it possible to identify micrometastasis that could not be identified by conventional imaging techniques such as computed tomography and bone scintigraphy. Hence, the concept of oligometastasis has been proposed [ 11 , 12 ].…”

Detection of recurrence sites using 18F-fluorocholine PET/CT in prostate cancer patients with PSA failure

“…has reported that the combination of FCH-PET/CT and multiparameter MRI may provide better treatment planning with increased diagnostic accuracy. 28 Thus, each institution must select a group of patients for whom PET/CT is helpful while using available radioactive tracers.…”